Canine Adenovirus 2: Respiratory Disease Reference

Overview and Taxonomy of Canine Adenovirus 2 (CAV-2)

Within the virological landscape of the Canidae, few agents illustrate the delicate balance between virulence, host adaptation, and immunological control as elegantly as Canine Adenovirus 2 (CAV-2). As a primary etiological agent within the Canine Infectious Respiratory Disease Complex (CIRDC), CAV-2 is responsible for a significant proportion of upper and lower respiratory tract infections in domestic dogs and wild canids worldwide. Its clinical presentation, ranging from subclinical carriage to severe infectious tracheobronchitis, underscores its role as a ubiquitous pathogen in high-density canine populations, including shelters, kennels, and breeding facilities [3, 15]. Despite the widespread availability of effective vaccines, CAV-2 remains a persistent challenge due to its ability to circulate asymptomatically and its frequent involvement in polymicrobial infections, which exacerbate clinical outcomes [1, 2, 4]. Understanding the fundamental taxonomy, structural biology, and genetic heterogeneity of CAV-2 is therefore not merely an academic exercise; it is essential for the rational design of diagnostic assays, the refinement of vaccine strategies, and the surveillance of emerging variants.

Taxonomically, CAV-2 is classified within the family Adenoviridae, genus Mastadenovirus, and is officially designated as a member of the species Canine mastadenovirus A [7, 9]. This species encompasses both CAV-1 and CAV-2, two serotypes that, despite significant genetic homology and antigenic cross-reactivity, exhibit markedly distinct pathogenic profiles and tissue tropisms. While CAV-1 is the archetypal agent of infectious canine hepatitis (ICH), a systemic disease characterized by hepatic necrosis, renal lesions, and the pathognomonic "blue eye" resulting from corneal edema, CAV-2 is primarily a respiratory pathogen, causing infectious laryngotracheitis and contributing to the broader syndrome of kennel cough [5, 14, 17]. The genetic divergence underlying this tropism is rooted in subtle variations within the capsid proteins, particularly the fiber and hexon, which govern receptor binding and cellular entry. CAV-2 preferentially attaches to ciliated epithelial cells of the respiratory tract, whereas CAV-1 exhibits a broader tropism for parenchymal organs such as the liver, kidney, and vascular endothelium. This differential receptor usage is a defining feature of the two serotypes and is critical for understanding their respective disease spectrums.

The CAV-2 virion is a non-enveloped icosahedral particle, approximately 70–90 nm in diameter, with a characteristic capsid architecture composed of three major structural proteins: hexon, penton base, and fiber [8, 16]. The double-stranded DNA genome, approximately 31–32 kilobases in length, is organized into early (E1–E4) and late (L1–L5) transcription units, a canonical feature of the mastadenoviruses. The hexon protein is the primary immunodominant antigen and the target of neutralizing antibodies; it contains seven hypervariable regions (HVRs) that determine serotype specificity and drive antigenic diversity [12, 18]. The fiber protein, projecting from each penton base at the vertices of the capsid, is responsible for high-affinity binding to the host cell receptor. For CAV-2, this receptor is believed to be the coxsackievirus and adenovirus receptor (CAR) or a related surface molecule, though precise binding mechanisms in canine cells remain an area of active investigation [19]. The fiber knob domain is also a major locus of genetic variation, as demonstrated by studies describing distinct fiber gene sequences among circulating strains, which may influence tissue tropism and immune evasion [12, 18]. Furthermore, the E3 region, a non-essential early gene module encoding proteins that modulate host immune responses, exhibits considerable variability. Notably, an insertion of a guanine nucleotide at position 1077 of the E3 gene in Indian isolates has been reported, resulting in a frameshift and an extended C-terminal tail of the E3 protein, a finding that may have implications for the functional role of this protein in intracellular immune modulation [6].

Phylogenetic analyses of CAV-2 isolates from diverse geographic locales have revealed a complex genetic architecture that challenges the notion of a single, monolithic serotype. Early genotypic characterization using DNA restriction endonuclease analysis identified isolates such as IAF-81-2116 and IAF-75-95 as distinct genotypic variants of CAV-2, suggesting that relatively minor changes in genomic sequence could permit replication at unusual anatomical sites, such as the intestinal tract [18]. More contemporary whole-genome and partial-gene sequencing studies have refined our understanding of CAV-2 evolution. Analyses based on the E3 gene have consistently delineated two major phylogenetic subgroups: a clade comprising isolates from America and Europe, and a second clade encompassing strains from China and Turkey, with amino acid differences of up to nine residues between the two groups [5]. Further expanding this framework, studies in central China have identified a novel genotype based on pairwise sequence comparisons of the hexon gene, thereby indicating that the genetic divergence of CAV-2 is more pronounced than previously appreciated [12]. Importantly, the fiber gene among Chinese isolates exhibited only 79.0–80.5% nucleotide identity with the widely used vaccine strain CLL, raising critical questions about the extent of antigenic drift and the potential for vaccine breakthrough [12]. A similar pattern has been observed in India, where a unique signature insertion in the E3 gene places local strains in a separate phylogenetic clade, reinforcing the concept of geographically restricted evolution [6]. These findings collectively suggest that CAV-2 is not a static entity but is actively diversifying, possibly driven by selective pressures from host immunity and vaccination.

The relationship between CAV-2 and its canonical vaccine strains, most notably the Toronto A26/61 strain isolated in Canada in 1961, is of paramount epidemiological importance. The Toronto strain serves as the backbone for most modified-live virus (MLV) vaccines and is also the progenitor of many recombinant CAV-2 vectors used in gene therapy and vaccine development [7, 10, 17, 20]. Full-genome sequencing of a Korean isolate (APQA1601) demonstrated 99.9% nucleotide identity with the Toronto A26/61 strain, indicating that the vaccine-derived lineage remains prevalent in certain populations [16]. More strikingly, the detection of CAV-2 strains genetically identical to Toronto A26/61 in wild raccoon dogs (Nyctereutes procyonoides) in Korea suggests a transmission pathway from vaccinated domestic animals into wildlife reservoirs [7]. This finding has profound implications for conservation biology and wildlife epidemiology, as it underscores the potential for vaccine-strain spillover into naive wild canid populations, with unknown consequences for ecosystem health. The World Organization for Animal Health (WOAH) recognizes the importance of monitoring such spillover events, as the introduction of vaccine-derived viruses into wildlife can disrupt endemic pathogen dynamics and compromise the health of endangered species.

Beyond its role as a respiratory pathogen, CAV-2 has become an indispensable tool in biomedical research and veterinary vaccinology. Its ability to infect a broad range of cell types, including Madin-Darby canine kidney (MDCK) and Vero cells, along with its capacity to accommodate large transgene inserts, has made it a platform of choice for developing recombinant vaccines and gene therapy vectors [6, 10, 13, 16, 19, 20]. E1-deleted, replication-defective CAV-2 vectors have been engineered to express heterologous antigens from pathogens such as Foot-and-Mouth Disease Virus (FMDV) and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), demonstrating robust immunogenicity in animal models [10, 20]. In the field of neuroscience, CAV-2 vectors carrying cell-type-specific promoters, such as the choline acetyltransferase (ChAT) promoter, have enabled targeted transgene expression in cholinergic interneurons of the striatum in non-human primates, providing a powerful tool for studying basal ganglia function and neurodegenerative diseases [13]. This dual identity of CAV-2, as both a naturally occurring canine pathogen and a versatile molecular tool, demands that researchers maintain a clear distinction between field strains, vaccine strains, and engineered recombinant vectors, particularly when interpreting diagnostic PCR results, as vaccine-derived nucleic acids can be detected for up to 28 days post-vaccination [11].

In summary, the taxonomy and biology of CAV-2 are defined by its membership in the species Canine mastadenovirus A, its clear serotypic distinction from CAV-1, and its ongoing genetic diversification across global canine populations. The structural proteins, hexon, fiber, and penton, are the primary determinants of serotype specificity, receptor tropism, and immune recognition, while the E3 gene serves as a hot spot for genetic variation that may influence host interactions. The phylogenetic division of strains into at least two major subgroups (America-Europe versus China-Turkey) and the identification of unique genetic signatures, such as the frameshift insertion in Indian isolates, highlight the dynamic evolutionary trajectory of this virus. This genetic heterogeneity has direct implications for the sensitivity of molecular diagnostic assays, the efficacy of current vaccines, and the potential for cross-species transmission into wildlife. As we continue to unravel the intricate relationship between CAV-2 and its hosts, a robust taxonomic and phylogenetic framework remains the cornerstone of effective surveillance, prevention, and intervention strategies.

Molecular Pathogenesis of CAV-2 in Respiratory Disease

The molecular pathogenesis of canine adenovirus type 2 (CAV-2) within the canine respiratory tract represents a multifaceted interplay between viral determinants of tropism, host cell receptor engagement, intracellular replication strategies, and the resulting immunopathological cascade. As a member of the genus Mastadenovirus within the family Adenoviridae, CAV-2 is a non-enveloped, double-stranded DNA virus that has evolved sophisticated mechanisms to exploit the respiratory epithelium, establishing infection that ranges from subclinical shedding to severe bronchopneumonia, particularly in the context of co-infections characteristic of the canine infectious respiratory disease complex (CIRDC) [2, 3, 21]. Understanding these molecular events at a granular level is essential for comprehending the virus's role as both a primary pathogen and a facilitator of secondary bacterial invasion.

Viral Architecture and Genomic Organization

The CAV-2 virion is an icosahedral particle approximately 70–90 nm in diameter, composed of a proteinaceous capsid surrounding a linear double-stranded DNA genome of roughly 31–32 kilobase pairs [5, 7]. The capsid is primarily constructed from three major structural proteins: the hexon, the penton base, and the fiber protein. The hexon protein constitutes the bulk of the capsid and is the primary target for neutralizing antibodies, while the fiber protein projects from each vertex of the icosahedron and is the critical determinant of primary cellular attachment [12, 16]. The penton base, interacting with the fiber, facilitates secondary internalization via integrin-mediated endocytosis. The genome is organized into early (E1–E4), intermediate, and late (L1–L5) transcription units, which are temporally regulated to orchestrate viral replication, host cell manipulation, and virion assembly. Notably, the E3 region, while non-essential for viral replication in vitro, encodes immunomodulatory proteins that are pivotal for evading host immune surveillance in vivo [5, 6]. The E3 gene has been a focus of molecular epidemiological studies, revealing that genetic variations in this region, such as the unique "G" nucleotide insertion at position 1077 observed in Indian CAV-2 isolates, can lead to a frameshift and an extended C-terminal tail in the E3 protein, potentially altering its functional capacity to modulate the host immune response [6]. Phylogenetic analyses of the E3 gene have further delineated CAV-2 into at least two major subgroups: an America-Europe clade and a China-Turkey clade, suggesting geographically distinct evolutionary pressures and potential differences in pathogenic potential [5].

Receptor-Mediated Entry and Cellular Tropism

The initial step in CAV-2 infection is the high-affinity binding of the fiber knob domain to a primary cellular receptor on the surface of respiratory epithelial cells. While the specific receptor for CAV-2 has not been definitively identified with the same clarity as for some human adenoviruses, comparative studies with other mastadenoviruses provide critical insights. For instance, human adenovirus serotype 7 (HAdV-7), a highly virulent respiratory pathogen, utilizes desmoglein-2 (DSG2), a desmosomal cadherin, for attachment [8]. Given the structural conservation among adenovirus fiber knobs, it is plausible that CAV-2 may engage a similar or related junctional protein on canine airway epithelial cells, facilitating infection at sites of cell-cell contact and potentially disrupting epithelial barrier integrity. Following fiber-mediated attachment, the penton base interacts with cellular integrins, primarily αvβ3 and αvβ5, via an Arg-Gly-Asp (RGD) motif. This interaction triggers clathrin-mediated endocytosis, delivering the virion into endosomal compartments. The acidic environment of the endosome then induces conformational changes in the viral capsid, leading to endosomal membrane disruption and release of the partially uncoated viral core into the cytoplasm. The core is subsequently trafficked to the nuclear pore complex, where the viral genome is imported into the nucleus to initiate transcription [19]. The tropism of CAV-2 is largely restricted to the respiratory epithelium, with the virus demonstrating a particular affinity for ciliated epithelial cells, goblet cells, and cells within the tonsillar crypts and tracheobronchial lymphoid tissue [5, 17]. This selective tropism is a primary determinant of the clinical syndrome, which typically manifests as an upper respiratory tract infection (pharyngitis, tonsillitis, laryngotracheitis) but can extend to the lower airways, particularly in young, immunologically naïve, or co-infected animals [3, 5].

Intracellular Replication and Cytopathic Effect

Once the viral genome is delivered to the nucleus, a tightly regulated transcriptional cascade ensues. The early genes (E1A, E1B, E2, E3, E4) are expressed first, functioning to transactivate other viral genes, drive the host cell into S-phase to create a permissive environment for viral DNA replication, and subvert host antiviral defenses. The E2 region encodes the viral DNA polymerase, preterminal protein, and DNA-binding protein, which are essential for the replication of the viral genome [19]. The late genes (L1–L5), expressed after the onset of DNA replication, encode the structural proteins required for assembling progeny virions. The production of CAV-2 within infected cells exerts a profound metabolic burden. Metabolic flux analysis of CAV-2-infected Madin-Darby Canine Kidney (MDCK) cells has revealed a significant upregulation of central carbon metabolism, including glycolysis, the pentose-phosphate pathway, and glutamine anaplerosis [19]. This metabolic reprogramming is driven by the high demand for nucleotides and lipids required for viral genome replication and capsid assembly. Notably, CAV-2 infection markedly increases reductive carboxylation of α-ketoglutarate and cytosolic acetyl-coenzyme A formation, indicative of enhanced lipogenesis, likely to support the production of viral membranes or to alter host cell membrane dynamics [19]. The cytopathic effect (CPE) of CAV-2 is characterized by rounding, detachment, and lysis of infected epithelial cells, observed in vitro as a "bunch of grapes" morphology [16]. This CPE is a direct consequence of viral replication and the shut-off of host protein synthesis, leading to cell death and the release of progeny virions that can then infect adjacent cells or be shed into the respiratory secretions.

Modulation of Host Antiviral Defenses and Immunopathogenesis

A critical aspect of CAV-2 pathogenesis is its ability to modulate the host immune response. The E3 region encodes proteins that interfere with the major histocompatibility complex (MHC) class I antigen presentation pathway, thereby reducing the recognition and killing of infected cells by cytotoxic T lymphocytes [6]. This immune evasion strategy allows the virus to establish a foothold in the respiratory tract and prolong the duration of infection and shedding. However, the host immune response is a double-edged sword. While necessary for viral clearance, the ensuing inflammatory response is a major contributor to the clinical signs of CIRDC. Infection of the respiratory epithelium triggers the release of a cascade of pro-inflammatory cytokines and chemokines, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and various chemokines that recruit neutrophils, macrophages, and lymphocytes to the site of infection [24]. This inflammatory infiltrate, while attempting to control the virus, also causes collateral damage to the respiratory mucosa, leading to increased mucus production, ciliary dysfunction, and epithelial necrosis. The resulting impairment of mucociliary clearance is a hallmark of CAV-2 infection and creates a permissive environment for secondary bacterial invaders, such as Bordetella bronchiseptica and Mycoplasma cynos, which are frequently co-detected in CIRDC cases [2-4]. Indeed, the synergistic interaction between CAV-2 and these bacteria is a central tenet of CIRDC pathogenesis. The virus-induced damage to the epithelial barrier and the suppression of local immune defenses allow bacteria to colonize the lower respiratory tract, leading to more severe and protracted disease [3, 4]. Furthermore, the presence of CAV-2 can exacerbate the inflammatory response to these bacteria, contributing to the development of bronchopneumonia.

Genetic Diversity and Pathogenic Potential

While CAV-2 is generally considered a pathogen of low to moderate virulence, genetic diversity among circulating strains can influence pathogenic potential. The fiber, hexon, and penton genes are the most variable regions of the CAV-2 genome, and mutations within these genes can alter receptor binding affinity, antigenicity, and tissue tropism [12]. For instance, sequence analysis of CAV-2 strains from central China revealed that the fiber gene harbors the most variant sites, with amino acid mutations predicted to cause structural changes in the head region of the fiber protein, which could potentially affect its interaction with the host cell receptor [12]. This genetic plasticity may allow the virus to adapt to different host populations or to escape vaccine-induced immunity. The emergence of novel genotypes, as suggested by pairwise sequence comparisons of the hexon gene, underscores the ongoing evolution of CAV-2 and the need for continued molecular surveillance [12]. The detection of CAV-2 in the feces of dogs with enteritis, and its occasional association with neurological symptoms, further suggests that under certain circumstances, the virus may exhibit a broader tropism than traditionally appreciated [6, 22]. The isolation of CAV-2 from a rectal swab of a dog with neurological signs, coupled with the unique E3 gene insertion, raises the possibility that specific genetic signatures could be linked to extra-respiratory manifestations, although the molecular mechanisms underlying such events remain poorly understood [6]. The widespread use of modified-live vaccines has significantly reduced the incidence of severe CAV-2 disease, but the virus continues to circulate in both domestic and wild canid populations, including raccoon dogs and foxes, serving as a potential reservoir for re-infection of vaccinated animals [7, 9, 23]. The high degree of genetic similarity between some wild CAV-2 isolates and the vaccine strain Toronto A26/61 suggests that vaccine-derived viruses may be shed and transmitted to naïve animals, highlighting the complex interplay between vaccination, viral evolution, and ecological transmission dynamics [7].

Epidemiology of CAV-2 in Canine Infectious Respiratory Disease Complex

Canine adenovirus type 2 (CAV-2) occupies a distinctive position within the etiological matrix of canine infectious respiratory disease complex (CIRDC), a multifactorial syndrome that remains one of the most common and economically burdensome health challenges in domestic dogs worldwide. Unlike its close relative, canine adenovirus type 1 (CAV-1), which causes infectious canine hepatitis and is subject to robust vaccine-induced immunity, CAV-2 is primarily a respiratory pathogen, though its epidemiological footprint is shaped by complex interactions with host factors, environmental conditions, vaccination practices, and the polymicrobial nature of the CIRDC itself. Understanding the epidemiology of CAV-2 requires not only an appreciation of its detection rates across diverse populations but also a critical examination of the methodological frameworks used to ascertain its presence, the role of co-infecting pathogens, and the increasingly recognized phenomenon of subclinical carriage that complicates our interpretation of causality.

Prevalence and Detection Rates Across Global Canine Populations

Contemporary molecular surveillance studies consistently report CAV-2 detection rates that range from approximately 2% to 13% in dogs presenting with respiratory signs, though these figures are highly dependent on the geographical region, the population studied, and the diagnostic platform employed. In a comprehensive five-year retrospective analysis of 459 CIRDC cases submitted to a veterinary diagnostic laboratory in Georgia, USA, CAV-2 was identified in only 4% of specimens, placing it behind canine parainfluenza virus (CPIV) at 16% and the mycoplasmas M. canis and M. cynos at 24% and 21%, respectively [2]. This pattern of relatively low CAV-2 prevalence relative to other CIRDC pathogens is corroborated by European data, where Day and colleagues synthesized peer-reviewed literature to conclude that CAV-2 and CDV recovery rates from both healthy and diseased dogs are low, a phenomenon they attribute largely to widespread vaccination [3]. Similarly, in a study of 214 dogs with respiratory disease in Austria, CAV-2 nucleic acid was detected in samples from the upper airways of only a small subset of dogs, with canine respiratory coronavirus (7.5%) and CPIV (6.5%) being far more commonly identified [28]. In Japan, a molecular survey conducted between 2017 and 2018 detected CAV-2 in a similarly modest proportion of dogs, with Bordetella bronchiseptica, canine herpesvirus 1, and CPIV all appearing more frequently [30]. These findings collectively suggest that in well-vaccinated companion animal populations, CAV-2 circulates at a low endemic level, often below the radar of routine diagnostics unless specifically targeted by multiplex panels.

However, the epidemiological picture shifts dramatically when one examines populations with high-density housing, such as shelters, kennels, and breeding facilities. In these environments, where vaccination histories are often unknown, stress levels are elevated, and pathogen introduction is frequent, CAV-2 detection rates can be substantially higher. A study of asymptomatic dogs presented at US animal shelters revealed that 12.5% of 503 dogs were PCR-positive for CAV-2, a figure that placed it among the most prevalent pathogens detected in that cohort, behind only M. cynos (29.2%) and B. bronchiseptica (19.5%) [36]. This finding is critical because it demonstrates that CAV-2 can be harbored asymptomatically in a substantial proportion of shelter dogs, creating a reservoir for transmission to incoming animals and contributing to the explosive outbreaks that characterize these environments. In a Turkish shelter study where respiratory infections were closely monitored, 2.5% of 155 nasal swabs were positive for CAV-2 by PCR targeting the E3 gene, with phylogenetic analysis revealing distinct subgroups of circulating strains [5]. Even more striking was the observation from the New Zealand canine population, where CAV-2 was more likely to be detected in healthy dogs (23%) than in those with clinical CIRDS (9%), a counterintuitive finding that challenges the assumption that CAV-2 detection necessarily implies causation [34]. This paradox underscores a fundamental epidemiological truth: the mere presence of CAV-2 nucleic acid in a respiratory sample does not establish it as the etiological agent of disease, particularly in populations where subclinical infection is common.

The Critical Confounder: Vaccine-Induced Positivity

One of the most significant challenges in interpreting CAV-2 epidemiological data is the confounding effect of modified-live virus (MLV) vaccines. CAV-2 is a core component of the DAPP (distemper, adenovirus, parainfluenza, parvovirus) combination vaccine, and it is also included in intranasal kennel cough vaccines alongside Bordetella bronchiseptica and CPIV. The prospective pilot study by Ruch-Gallie and colleagues demonstrated definitively that nucleic acids of all three organisms contained in the topical intranasal vaccine could be detected from both nasal and pharyngeal swabs for up to 28 days after vaccination, with the highest number of positive samples occurring between days 3 and 10 [11]. This finding has profound epidemiological implications: a positive PCR result for CAV-2 in a dog presenting with respiratory signs could merely reflect recent vaccination rather than active infection with a field strain. The authors explicitly caution that vaccine status must be considered when interpreting respiratory agent PCR results, and they advocate for the development of quantitative PCR assays and wild-type sequencing to improve the positive predictive value of these diagnostic tools by distinguishing vaccine from natural infection [11]. The WOAH (World Organisation for Animal Health) and the CDC, in their guidance on canine respiratory disease surveillance, have similarly emphasized the importance of contextualizing molecular diagnostic results with vaccination history, though such nuanced interpretation is often lacking in field studies and diagnostic laboratory reports. Given that the vast majority of companion dogs in developed nations receive regular MLV vaccines containing CAV-2, it is plausible that a non-trivial proportion of the CAV-2 detections reported in epidemiological surveys may, in fact, represent vaccine-derived nucleic acid rather than evidence of circulating virulent virus. This confound may partially explain the low pathogenicity of CAV-2 observed in many studies and the difficulty in establishing clear causal links between CAV-2 detection and clinical disease.

Co-Infection Dynamics and the Polymicrobial Nature of CIRDC

CAV-2 very rarely acts as a sole respiratory pathogen; rather, it operates within a complex polymicrobial ecosystem. The epidemiological literature is replete with evidence that CAV-2 is frequently detected in co-infections with other viral and bacterial agents, complicating efforts to attribute clinical signs to any single organism. In the multiplex PCR panel study by Thieulent and colleagues, which tested 76 clinical specimens from CIRDC-suspected dogs, M. canis, M. cynos, and CRCoV were the most frequently identified pathogens, but co-infections were identified in 30.3% of samples [21]. Similarly, in the large-scale investigation by Dong and colleagues of 740 clinical samples using a nine-pathogen multiplex real-time PCR panel, co-infections were identified in 60 of the 139 positive samples, demonstrating that the presence of one pathogen frequently predicts the presence of others [25, 29]. The work of Piewbang and colleagues in Thailand, which included 209 dogs with respiratory illness, found that multiple virus detection occurred in 81.2% of community-acquired infections and 78.9% of hospital-associated infections, with co-detection of CIV and CRCoV representing the highest proportion of mixed infections, often alongside CAV-2 [27]. These data align with the broader understanding that CIRDC is a syndemic disease in which viral pathogens like CAV-2 may cause epithelial damage that facilitates secondary bacterial invasion, or where the immunosuppressive effects of one virus create permissive conditions for another.

The biological mechanisms underpinning this synergy are increasingly well understood. CAV-2, as a double-stranded DNA virus, infects and replicates within respiratory epithelial cells, causing cell lysis and disruption of the mucociliary apparatus. This damage compromises the physical barrier and innate immune defenses of the respiratory tract, creating an environment conducive to the adherence and proliferation of bacterial pathogens such as B. bronchiseptica and Streptococcus equi subsp. zooepidemicus. Furthermore, CAV-2 has been shown to modulate the host immune response, potentially through the action of its E3 region proteins, which are involved in immune evasion by downregulating major histocompatibility complex class I expression. This immune modulation may facilitate co-infection by other viruses, such as CPIV or CRCoV, that would otherwise be more efficiently cleared. The study by Maboni and colleagues, which employed statistical modeling to analyze CIRD pathogens, emphasized that co-infections have a profound impact on the severity of clinical presentation and that host factors, particularly animal age, are the most important predictors of disease severity [4]. Importantly, they found that the presence of M. cynos was significantly associated with more severe respiratory signs, and this pathogen was frequently found alongside CAV-2 and other viruses [3, 4]. From an epidemiological surveillance standpoint, this co-infection dynamic means that focusing solely on CAV-2 prevalence without considering the broader pathogen community provides an incomplete and potentially misleading picture of the forces driving respiratory disease in a given population.

Host Susceptibility, Age, and Environmental Risk Factors

The epidemiology of CAV-2 is not uniform across all dogs; rather, it is modulated by well-defined host and environmental risk factors. Age is among the most consistent predictors of CAV-2 infection and disease. Young dogs, particularly those under six months of age, are disproportionately affected, a pattern that reflects the waning of maternally derived antibodies before the completion of the primary vaccination series. In the study by Chethan and colleagues, which focused on enteric disease but included CAV-2 detection, the highest occurrence of infection was in the 0–3 month age group [33]. While that study examined CAV-1 predominantly, the biological principle applies equally to CAV-2: young animals with immature immune systems and incomplete vaccination are most vulnerable. Conversely, older dogs that have received regular booster vaccinations are generally well-protected against clinical disease, though they may still become subclinically infected and serve as shedders. The serological survey conducted in Korea by Yang and colleagues, which tested 1,028 dog sera using a virus neutralization test, found an 88.5% seropositivity rate for CAV-2, indicating widespread exposure or vaccination, but the vast majority of these animals had titers consistent with vaccine-induced immunity rather than recent natural infection [32].

Environmental factors exert a powerful influence on CAV-2 transmission dynamics. The virus is transmitted primarily via direct contact with infected respiratory secretions, but it can also be spread through fomites and aerosols, particularly in crowded, poorly ventilated spaces. Shelters and kennels, therefore, represent high-risk environments. The study by Andrukonis and colleagues, conducted during a CIRD outbreak in a city shelter in West Texas, demonstrated that all 15 tested dogs were positive for at least one pathogen, with CDV being the most prevalent, but CAV-2 was also identified among the mixed infections [26]. The introduction of an intake vaccination protocol, which included a CAV-2-containing DAPP vaccine, led to a significant 7% reduction in the proportion of dogs coughing once vaccination coverage reached 90% [26]. This finding provides compelling evidence that vaccination-based interventions can disrupt transmission cycles in high-density populations, even during active outbreaks. However, the study by Lavan and Knesl, which examined asymptomatic shelter dogs across the United States, found that 12.5% harbored CAV-2 [36], highlighting that even vaccinated populations can maintain a reservoir of infection. The concept of “silent shedding” is critical for shelter medicine practitioners: dogs that appear healthy may still be capable of transmitting CAV-2 to susceptible cohorts, particularly young puppies or immunocompromised adults.

Seroprevalence and Exposure in Wildlife Reservoirs

The epidemiology of CAV-2 extends beyond the domestic dog population, with growing evidence that wild canids and other species serve as reservoirs or spillover hosts. A serological survey in Korea that included 160 raccoon dogs (Nyctereutes procyonoides) found a 51.3% seropositivity rate for CAV-2 neutralizing antibodies, with 8.8% of these animals having titers over 1:256, indicative of recent or repeated natural infection [32]. This finding is echoed by the work of Kim and colleagues, who isolated CAV-2 from wild raccoon dogs in Korea and found that the virus was genetically highly similar to the Toronto A26/61 vaccine strain, suggesting that transmission may have occurred from vaccinated domestic dogs to wildlife populations [7]. This interspecies transmission raises important questions about the safety of MLV vaccines in ecosystems where domestic and wild canids overlap. The WOAH recognizes the potential for vaccine virus transmission to wildlife as a biosafety concern, and these data from Korea provide empirical evidence that such transmission is not merely theoretical.

In a study of free-ranging red foxes (Vulpes vulpes) in the United Kingdom, Walker and colleagues found that 64.4% were seropositive for canine adenovirus by ELISA, though CAV-2 was not detected by PCR in any of the foxes examined, while CAV-1 was identified in 18.8% of foxes with inapparent infections across multiple tissue types [9]. This suggests that while foxes are exposed to canine adenoviruses, CAV-2 may not establish the same persistent or disseminated infections in foxes as CAV-1 does. In contrast, serosurveys of Arctic foxes (Vulpes lagopus) in Norway and red foxes in the Low-Arctic and sub-Arctic regions found seroprevalence rates for canine adenovirus ranging from 31% to 80% over multiple seasons, indicating that CAdV is enzootic in these populations [23]. The study by Canuti and colleagues, which investigated gray wolves (Canis lupus) in northern Canada over 13 years, found CAV-1 in 1% of animals but did not specifically identify CAV-2, though the authors noted the co-circulation of multiple parvoviruses [31]. These wildlife data collectively indicate that CAV-2 and its close relatives have a broad host range among canids and that wildlife populations may act as sentinels for viral circulation, as well as potential reservoirs for re-introduction into domestic dogs in regions where vaccination coverage is low or waning.

Genotypic Diversity and Molecular Epidemiology

The molecular epidemiology of CAV-2 reveals significant genetic diversity that may have implications for pathogenesis, vaccine efficacy, and diagnostic accuracy. The E3 gene, which encodes proteins involved in immune modulation, has been a particular focus of study. Sequencing of the E3 region from Turkish CAV-2 isolates by Timurkan and colleagues revealed 97.7–98.9% similarity among local viruses, but phylogenetic analysis demonstrated that Turkish and Chinese strains formed a distinct subgroup separate from American-European isolates [5]. This subdivision into at least two genotypic groups, designated “China-Turkey” and “America-Europe”, suggests that CAV-2 is undergoing geographic differentiation that may reflect independent evolutionary trajectories in different regions. More strikingly, the study by Chander and colleagues in India identified a unique insertion of a guanine nucleotide at position 1077 in the E3 gene of Indian CAV-2 isolates, which introduced a frameshift and resulted in an additional eleven amino acids at the C-terminal end of the E3 protein compared to isolates from other parts of the world [6]. This insertion may alter the functional properties of the E3 protein, potentially affecting the virus’s ability to evade the host immune response. The same study also reported an association between CAV-2 and neurological disease in a vaccinated dog, a finding that is exceptionally rare and suggests that E3 gene variants could be linked to altered tissue tropism or pathogenicity.

The hexon, fiber, and penton genes, which encode the major capsid proteins and are the primary targets of neutralizing antibodies, also exhibit variability. Ji and colleagues conducted a comprehensive investigation of CAV-2 in central China and found that the fiber gene sequences of 19 strains shared only 79.0–80.5% nucleotide and 77.3–80.5% amino acid identity with the vaccine strain CLL, whereas the hexon and penton sequences were more conserved (97.4% identity) [12]. Protein model prediction indicated that the amino acid mutations in the fiber protein were located in the head region, which is responsible for receptor binding, suggesting that these changes could alter viral attachment to host cells. Furthermore, pairwise sequence comparisons of the hexon gene from Chinese strains with an Indian strain from 2006 revealed a novel genotype, indicating that the classification of CAV-2 strains may need to be revised to reflect the true extent of genetic diversity [12]. For epidemiologists and vaccine manufacturers, these findings underscore the need for ongoing molecular surveillance to ensure that vaccines remain antigenically matched to circulating field strains. The WHO and WOAH have both emphasized the importance of monitoring antigenic drift in veterinary vaccine-preventable diseases, and these data on CAV-2 suggest that such surveillance is warranted.

Temporal Trends and the Impact of Non-Pharmaceutical Interventions

The COVID-19 pandemic has provided a natural experiment that has reshaped the epidemiology of respiratory pathogens worldwide, and CAV-2 is no exception. The widespread implementation of non-pharmaceutical interventions (NPIs) such as social distancing, mask-wearing, and lockdowns in 2020–2022 dramatically reduced the circulation of many respiratory viruses, including human adenoviruses [35, 37, 38]. In South Korea, the adenovirus detection rate in humans dropped from a mean of 8.2% in 2019 to 6.1% during the pandemic, only to surge to 14.3% by the 36th week of 2023, with a peak of 42.2% [35]. While these data are from human surveillance, the principles apply to canine populations: reduced social mixing of dogs during lockdowns, decreased visits to boarding kennels, and lower rates of shelter intake likely led to reduced transmission of CAV-2 and other CIRDC pathogens. Subsequent relaxation of restrictions has allowed these pathogens to rebound, potentially creating a scenario of “immune debt” analogous to that observed in humans for respiratory syncytial virus and influenza. Veterinary practitioners should be alert to the possibility of increased CAV-2 activity in the post-pandemic period, particularly in populations where routine vaccination was disrupted during the height of the pandemic. The study by Zhao and colleagues, which examined respiratory pathogens in human patients in China before and after the easing of COVID-19 restrictions, documented a significant increase in positivity rates for both influenza A virus and adenovirus in 2023 compared to the prior two years, a pattern that may well

Clinical Manifestations and Histopathology of CAV-2 Infection

1. Clinical Manifestations

Canine adenovirus type 2 (CAV-2) is a primary etiological agent of the canine infectious respiratory disease complex (CIRDC) and is principally associated with a syndrome historically termed "kennel cough" or infectious tracheobronchitis. The clinical manifestations of CAV-2 infection are highly dependent on a constellation of host factors, including age, immune status, vaccination history, and the presence of concurrent infections with other viral or bacterial pathogens [2-4, 21, 26]. The disease spectrum ranges from subclinical or inapparent infections, which are particularly common in vaccinated or immunocompetent adult dogs, to severe, life-threatening bronchopneumonia in naïve puppies and immunocompromised individuals [5, 17].

The hallmark clinical sign is a paroxysmal, dry, hacking cough that is often exacerbated by excitement, exercise, or pressure on the trachea. This cough is frequently productive, culminating in gagging or retching with the expulsion of mucus. In uncomplicated cases, affected dogs typically remain bright, alert, and maintain a normal appetite, distinguishing CAV-2 tracheobronchitis from systemic illnesses like canine distemper. As documented in experimental infections of specific-pathogen-free (SPF) Beagles, mild upper respiratory signs, including pharyngitis and enlarged tonsils, are the most consistent findings following intranasal inoculation [17]. Ocular signs are conspicuously absent in CAV-2 infection, a critical differentiating feature from canine adenovirus type 1 (CAV-1), which frequently causes anterior uveitis and corneal edema ("blue eye") [17].

However, the clinical picture can rapidly escalate in severity. The progression from a simple tracheobronchitis to a more fulminant pneumonia is a hallmark of CAV-2 pathogenesis, particularly when the virus invades the lower respiratory tract. Clinical indicators of pneumonia include a shift from a dry cough to a soft, moist cough accompanied by purulent nasal discharge. Tachypnea, dyspnea, pyrexia, lethargy, and anorexia are common. In severe cases, dogs may exhibit an "abdominal lift" during expiration and adopt an orthopneic posture with elbows abducted to facilitate lung expansion. Auscultation of the thorax may reveal crackles (rales) and wheezes, indicative of airway narrowing and fluid accumulation in the alveoli. The disease can be fatal in very young puppies due to airway obstruction by exudate and the resulting hypoxemia [5, 6, 14].

A critical aspect of the clinical presentation is the high frequency of co-infections. CIRDC is a multifactorial syndrome, and CAV-2 rarely acts alone. Epidemiological studies consistently demonstrate that CAV-2 is often detected concurrently with other pathogens, most notably Mycoplasma cynos, Bordetella bronchiseptica, canine parainfluenza virus (CPIV), and canine respiratory coronavirus (CRCoV) [2, 4, 14, 21, 22, 25, 27]. Co-infections are not merely incidental; they are synergistic, leading to a significantly more severe clinical course. The presence of M. cynos, for instance, has been statistically associated with more severe respiratory signs [3]. In a study of puppies that died suddenly, all cases with CAV-2 co-detection had triple or quadruple infections involving canine distemper virus, CAV-1, and canine parvovirus-2, resulting in severe interstitial pneumonia and necrohemorrhagic hepatitis [14]. This underscores that CAV-2 often acts as a "team player" in CIRDC, where its pathogenicity is amplified by the presence of other agents.

It is also important to recognize that CAV-2 infection can be detected in a substantial proportion of clinically healthy dogs, particularly those in high-density environments like shelters. Studies have shown that 12.5% of asymptomatic shelter dogs may be PCR-positive for CAV-2 [36]. These animals serve as a significant reservoir for viral shedding, perpetuating outbreaks within the population. The clinical significance of a positive PCR result must therefore be interpreted in the context of the dog’s signalment, clinical signs, and vaccination history, as modified live vaccines can lead to false-positive results for up to 28 days post-vaccination [11].

A rare but important clinical manifestation is the association of CAV-2 with neurological disease. While this is far more characteristic of CAV-1, a case report documented CAV-2 isolation from a vaccinated dog presenting with both respiratory and neurological symptoms, testing negative for other neurotropic pathogens like canine distemper virus [6]. The isolate possessed a unique insertion in the E3 gene, which may influence viral tropism and pathogenesis. This finding, while exceptional, expands the potential clinical spectrum of CAV-2 and warrants consideration in cases of non-suppurative encephalitis of unknown origin.

2. Histopathology

The histopathological lesions of CAV-2 infection are primarily confined to the respiratory tract and reflect the virus's tropism for ciliated epithelial cells lining the airways. The virus gains entry via the respiratory route, attaching to cellular receptors such as desmoglein-2, and replicates in the mucosal epithelium of the nasal cavity, pharynx, trachea, bronchi, and bronchioles [8, 17].

The earliest microscopic changes are observed in the tracheal and bronchial epithelium. The initial pathological event is a focal necrosis of ciliated epithelial cells. Infected cells undergo a characteristic cytopathic effect: they become enlarged and rounded, and the nucleus swells, losing its normal chromatin pattern. The most distinctive histopathological hallmark of adenovirus infection is the development of intranuclear inclusion bodies. These are initially eosinophilic (Cowdry type A inclusions), but as the infection progresses, they become large, basophilic, and fill the entire nucleus, often giving it a "smudged" appearance. The margination of chromatin at the nuclear membrane creates a clear halo around the inclusion. These inclusions are composed of crystalline arrays of viral particles. The necrotic epithelial cells desquamate into the airway lumen, where they contribute to the formation of an exudate composed of mucus, fibrin, and inflammatory cells, primarily neutrophils.

In the trachea and bronchi, the lamina propria becomes congested and edematous, with an infiltration of mononuclear cells, including lymphocytes, plasma cells, and macrophages. This inflammation, combined with the loss of ciliated epithelium and the presence of luminal exudate, impairs mucociliary clearance, predisposing the dog to secondary bacterial infections. The submucosal mucous glands undergo hyperplasia and hypertrophy, contributing to the characteristic hacking cough.

The severity of the disease is determined by the extent of viral invasion into the lower respiratory tract, leading to bronchiolitis and interstitial pneumonia. In severe cases, the terminal bronchioles are filled with a sloughed necrotic epithelium and neutrophils. The surrounding alveolar walls become thickened due to congestion, edema, and infiltration of macrophages and lymphocytes. The alveolar spaces may contain a proteinaceous fluid (edema), fibrin, and hemorrhage. In the most severe cases of necrotizing bronchopneumonia, there is extensive destruction of the bronchiolar and alveolar architecture, leading to the formation of hyaline membranes lining the alveolar ducts and sacs, a hallmark of acute respiratory distress syndrome (ARDS). This severe pathology is more commonly observed in cases of co-infection with other pathogens [14, 39].

Macroscopically, the lungs of severely affected dogs are heavy, edematous, and fail to collapse. They often exhibit a mottled appearance with areas of red to purple consolidation alternating with areas of compensatory emphysema. The airways may be filled with a frothy, mucopurulent exudate. Petechial and ecchymotic hemorrhages are frequently observed on the pleural surface and within the pulmonary parenchyma. Tracheobronchial lymph nodes are typically enlarged and edematous.

An important comparative histopathological point is the clear distinction between CAV-1 and CAV-2. As established in seminal experimental studies, CAV-1 infection causes ocular disease with anterior uveitis and corneal opacification, and it persists in renal tubular epithelium leading to nephritis. In stark contrast, CAV-2 is not found in ocular tissues, and viral replication in renal tissue is not demonstrated [17]. The "blue eye" phenomenon and characteristic kidney lesions are definitively associated with CAV-1 and are absent in pure CAV-2 infection. This tissue tropism difference is a key diagnostic and pathological feature that underscores the distinct pathogenic mechanisms of the two serotypes, despite their antigenic cross-reactivity.

In summary, the clinical and pathological picture of CAV-2 infection is one of a highly contagious, primarily upper respiratory tract infection that can progress to severe, life-threatening pneumonia under the influence of age, immune compromise, and the critical context of co-infection. The characteristic histopathology of necrotizing tracheobronchitis with intranuclear inclusion bodies provides a definitive diagnostic feature, while the clear clinical and pathological distinction from CAV-1 is essential for accurate diagnosis and case management. The infection is recognized by the World Organisation for Animal Health (WOAH) as a significant pathogen within the canine respiratory disease complex, and its control through vaccination is a cornerstone of shelter and kennel biosecurity.

Diagnostic Strategies for CAV-2: From Traditional to Multiplex Molecular Assays

The accurate and timely diagnosis of canine adenovirus type 2 (CAV-2) is a cornerstone of effective management for canine infectious respiratory disease complex (CIRDC). The diagnostic landscape for CAV-2 has undergone a profound transformation over the past several decades, evolving from classical virological and serological methods to the current era of highly sensitive, specific, and multiplex molecular assays. This evolution has been driven by the recognition of CAV-2 as a component of a polymicrobial syndrome, the need for rapid turnaround times to inform clinical decisions and outbreak control, and the imperative to differentiate vaccine-derived nucleic acids from wild-type infection [11]. The transition from traditional techniques to advanced molecular platforms not only reflects broader trends in veterinary diagnostics but also addresses the unique challenges posed by the pathogen's biology, its frequent involvement in co-infections, and its variable prevalence across different populations and geographies.

Foundational Traditional Methods: Virus Isolation and Serology

Historically, the gold standard for CAV-2 detection was virus isolation (VI) in permissive cell lines. Madin-Darby canine kidney (MDCK) cells and Vero cells have been the substrates of choice for propagating CAV-2 from clinical specimens such as nasal, pharyngeal, or tonsillar swabs, as well as from tissue homogenates [5, 16]. The hallmark cytopathic effect (CPE) induced by CAV-2, typically characterized by rounding, refractility, and the formation of grape-like clusters, provided a presumptive identification, which was then confirmed by immunofluorescence assay (IFA) using specific antisera, electron microscopy (EM), or hemagglutination (HA) assays [16]. While VI is highly specific, its sensitivity is limited by the requirement for viable, infectious virus in the sample, which is heavily dependent on appropriate collection, transport, and storage conditions. Furthermore, the process is labor-intensive, slow (requiring several days to weeks for CPE to develop), and not amenable to high-throughput testing, making it impractical for routine clinical diagnostics or large-scale epidemiological surveys.

Serological assays, including virus neutralization (VN) tests and enzyme-linked immunosorbent assays (ELISAs), have been employed to detect antibodies against CAV-2, providing evidence of past exposure or vaccination. The VN test, which measures the titer of neutralizing antibodies in serum, remains a reference method for assessing immune status and has been used extensively in serosurveys to determine population-level exposure [9, 32, 45]. For example, a large-scale serosurvey in Korea demonstrated a high seroprevalence of CAV-2 neutralizing antibodies in dogs (88.5%), highlighting widespread exposure or vaccine-induced immunity [32]. However, serology cannot distinguish between antibodies generated by natural infection and those from vaccination, nor can it differentiate between CAV-2 and antibodies cross-reactive with canine adenovirus type 1 (CAV-1), which is antigenically related [9, 17]. Most critically, serology is of no value for diagnosing active, acute infection, as it requires paired acute and convalescent sera to demonstrate a rising antibody titer, a delay that is incompatible with clinical decision-making. These inherent limitations of traditional methods have spurred the development and widespread adoption of nucleic acid-based diagnostics.

The Advent and Refinement of PCR-Based Detection

The application of the polymerase chain reaction (PCR) revolutionized the detection of CAV-2, offering unparalleled sensitivity, specificity, and speed compared to cell culture. Conventional (endpoint) PCR assays, typically targeting highly conserved genetic regions such as the E3 gene or the hexon gene, were among the first molecular tools developed for CAV-2 detection [5, 44]. These assays could amplify minute amounts of viral DNA from a variety of clinical samples, providing a rapid diagnosis within a matter of hours. For instance, a study in Turkey used a conventional PCR targeting the E3 gene to detect CAV-2 in nasal swabs from shelter dogs, achieving a detection rate of 2.5% and subsequently enabling phylogenetic analysis of the circulating strains [5]. While conventional PCR represented a major step forward, its reliance on post-amplification processing (gel electrophoresis) made it semi-quantitative at best and increased the risk of amplicon contamination. This led to the rapid transition to real-time or quantitative PCR (qPCR).

Real-time PCR assays for CAV-2, typically employing TaqMan probe-based chemistry, addressed many of the limitations of conventional PCR. The inclusion of a sequence-specific probe allows for the real-time monitoring of amplification, enabling quantification of the viral DNA load, eliminating the need for post-PCR manipulation, and significantly reducing turnaround time. The analytical sensitivity of these assays is exceptionally high, with detection limits frequently reported in the range of 1 to 10 copies per reaction [1, 21, 29]. Dong et al. validated a comprehensive nine-pathogen qPCR panel, reporting a limit of detection (LOD) of just 1 copy/μL for CAV-2 plasmid DNA [29]. Similarly, Thieulent et al. demonstrated robust performance in their four-plex qPCR panel for CAV-2 detection, with excellent linearity and efficiency [21]. This high sensitivity is critical, as CAV-2 may be present in low copy numbers in clinical samples, particularly in subclinical carriers or during early infection [36]. However, the extreme sensitivity of molecular assays also presents a challenge: the detection of vaccine virus nucleic acid. Following administration of modified live intranasal vaccines, which contain CAV-2, viral nucleic acids can be detected by PCR in nasal and pharyngeal swabs for up to 28 days post-vaccination [11]. This finding has profound implications for diagnostic interpretation, particularly in outbreak investigations in shelters or kennels where mass vaccination is common. It underscores the critical need for clinicians and diagnosticians to consider recent vaccine history and, ideally, to utilize quantitative assays or sequencing to help differentiate between vaccine and wild-type strains.

The Paradigm Shift: Multiplex Molecular Assays for CIRDC

The most significant advancement in CAV-2 diagnostics has been the development and validation of multiplex panels. The rationale for this approach is grounded in the fundamental ecology of CIRDC, which is a polymicrobial syndrome characterized by high rates of pathogen co-detection and co-infection [2, 4, 14, 27]. Single-target assays, while useful, are inefficient and diagnostically incomplete for a syndrome with a broad differential. Multiplex qPCR and RT-qPCR assays can simultaneously detect and differentiate CAV-2 alongside a wide array of other viral (e.g., CPIV, CDV, CRCoV, CIV, CHV-1) and bacterial (e.g., B. bronchiseptica, M. cynos, M. canis, S. zooepidemicus) pathogens from a single clinical specimen [1, 21, 25, 29, 42].

These panels are not merely a convenience; they are a necessity for capturing the true complexity of CIRDC. Studies utilizing these comprehensive panels have consistently revealed that a substantial proportion of dogs presenting with respiratory signs are infected with multiple pathogens, and that the clinical severity can be influenced by the specific combination of agents present [4]. For example, Thieulent et al. developed a panel of four one-step multiplex qPCR/RT-qPCR assays capable of identifying 12 CIRDC-associated pathogens, including SARS-CoV-2 [21]. In a clinical validation study of 76 specimens, they found co-infections in 30.3% of samples, highlighting the syndromic nature of the disease. Similarly, Shi et al. established a quadruplex RT-qPCR for CCoV, CRCoV, CAV-2, and CNV, demonstrating high specificity and sensitivity with LODs of 1.0 × 10² copies/reaction for each target [1]. The clinical applicability of such an assay was confirmed by testing 1,688 clinical samples, yielding a CAV-2 positivity rate of 2.84% [1]. Hao et al. developed two separate multiplex PCRs for respiratory and enteric viruses, allowing for the simultaneous detection of CAV-2, CDV, CIV, and CPIV in one reaction [42].

The design of these multiplex panels requires meticulous optimization. Target genes must be carefully selected to ensure specificity for each pathogen. For CAV-2, the hexon gene is a frequent target due to its conservation and role in serotype specificity [1, 12]. Primer and probe concentrations must be balanced to avoid competition and ensure uniform amplification efficiency across all targets. Dong et al. demonstrated that their three-panel multiplex assay maintained excellent amplification efficiencies (90.6-107.8%) and correlation coefficients (>0.993) for all targets, confirming that multiplexing did not compromise analytical performance [29]. Furthermore, control experiments showing that a high concentration of one target did not interfere with the detection of a low-concentration target in the same reaction provided critical evidence of the assay's robustness [25]. This technical rigor is essential for the reliable interpretation of complex, multi-pathogen results.

Rapid and Point-of-Care Alternatives: Isothermal Amplification

While real-time PCR remains the gold standard for its sensitivity and throughput, it requires sophisticated, expensive thermal cycling equipment and skilled personnel, which can be a barrier to its use in point-of-care (POC) or resource-limited settings. Isothermal amplification technologies, such as recombinase polymerase amplification (RPA), offer a compelling alternative by enabling DNA amplification at a constant low temperature (e.g., 39°C), eliminating the need for a thermocycler [40]. Xiao et al. developed and validated a real-time CAV-2 RPA assay that was capable of detecting the virus within 15 minutes at 39°C [40]. The assay demonstrated a detection limit of 214 copies/μL of DNA per reaction, which is somewhat less sensitive than qPCR, but its speed and simplicity are significant advantages for POC applications. The RPA assay showed a 97.7% coincidence rate with a reference qPCR when testing 86 field samples, indicating its potential as a reliable rapid diagnostic tool, particularly in outbreak settings or shelters where immediate results are needed to guide decisions on isolation and treatment [40]. The rapidity of RPA is particularly valuable given that the clinical window for effective intervention in CIRDC is often short.

Genetic Characterization and Sequencing

Beyond mere detection, detailed genetic characterization of CAV-2 is essential for molecular epidemiology, evolutionary studies, and vaccine strain monitoring. Partial or full-genome sequencing of the hexon, fiber, penton, and E3 genes provides the resolution needed to differentiate between circulating strains, identify novel genotypes, and track the geographic spread of specific variants [5, 7, 12]. Phylogenetic analysis of the E3 gene has revealed distinct genetic clusters, including a subgroup comprised of Turkish and Chinese isolates that is separate from the classical American-European clade [5]. Furthermore, studies have identified unique molecular features, such as a "G" nucleotide insertion in the E3 gene of Indian isolates, resulting in a frameshift and an extended C-terminal end of the E3 protein, which may have implications for viral pathogenesis [6]. Ji et al., through sequencing of the hexon, fiber, and penton genes of 19 Chinese field strains, identified a novel genotype and noted that the fiber gene harbored the most variation between field and vaccine strains, raising questions about the long-term efficacy of existing vaccines [12]. Sanger sequencing and next-generation sequencing (NGS) approaches are now routinely used to confirm the identity of pathogens detected by PCR, particularly in cases where the clinical presentation is atypical or where co-infections make interpretation of initial results difficult [6, 25]. NGS of pooled samples can also provide an unbiased, comprehensive view of the entire respiratory virome, as demonstrated by Song et al. in their discovery of canine pneumovirus in China [41] and More et al. in New Zealand [34], illustrating the power of these tools for the surveillance of both known and emerging pathogens.

Biosafety and One Health Considerations

The diagnostic approach to CAV-2 must also be considered within the broader context of biosafety and One Health. While CAV-2 is not a recognized zoonotic pathogen, its presence in a clinical sample signals the dog's involvement in a complex infectious disease ecosystem that can include zoonotic agents such as Bordetella bronchiseptica (an infrequent cause of respiratory disease in immunocompromised humans) and, rarely, SARS-CoV-2 [21]. The development of comprehensive multiplex panels that include SARS-CoV-2, as pioneered by Thieulent et al., highlights the public health utility of such tools [21]. From a WOAH (World Organisation for Animal Health) perspective, the differential diagnosis of CAV-2 from more reportable or economically significant pathogens, such as CAV-1 (infectious canine hepatitis), is crucial for international trade and disease control, as CAV-1 is a listed disease in the WOAH Terrestrial Animal Health Code. The ability to rapidly and definitively confirm CAV-2, while excluding CAV-1 through serotype-specific molecular assays or sequencing, is thus a critical diagnostic function. Furthermore, the use of CAV-2 as a vaccine vector for other diseases, including foot-and-mouth disease (FMD) [10] and SARS-CoV-2 [43], adds another layer of complexity. Diagnostic assays must be capable of distinguishing between natural CAV-2 infection and the presence of replication-defective recombinant CAV-2 vectors used in vaccination, a challenge that will require ongoing assay design and validation.

Prevention and Control: Vaccination and Biosecurity Measures

The control of Canine Adenovirus Type 2 (CAV-2) within the canine infectious respiratory disease complex (CIRDC) requires a multi-pronged strategy that integrates robust vaccination protocols with stringent biosecurity measures. Given that CAV-2 is a primary viral agent contributing to the syndrome, and that co-infections with other viral and bacterial pathogens, including Bordetella bronchiseptica, canine parainfluenza virus (CPIV), canine respiratory coronavirus (CRCoV), and Mycoplasma cynos, are the rule rather than the exception [2, 3, 21], a comprehensive preventive approach is essential. The efficacy of these measures is contingent upon an understanding of the virus’s epidemiology, transmission dynamics, and the immunological principles underlying vaccine-induced protection.

Vaccination: The Cornerstone of Prevention

Vaccination against CAV-2 is a standard component of core canine vaccination protocols globally. The primary rationale is the induction of a robust, protective immune response that reduces the incidence of clinical disease, viral shedding, and transmission, thereby establishing herd immunity within susceptible populations.

Historical Context and Vaccine Evolution: The earliest vaccines targeting canine adenoviruses utilized modified-live CAV-1 strains. However, these were associated with significant post-vaccinal adverse effects, most notably ocular lesions (anterior uveitis and corneal edema, often termed “blue eye”) and renal pathology [17]. This observation led to a critical shift in vaccinology. Research demonstrated that CAV-2, while sharing antigenic cross-reactivity with CAV-1, conferred cross-protection against CAV-1 challenge without inducing the same deleterious ocular and renal side effects [17]. Consequently, CAV-2 strains became the backbone of modern multivalent vaccines (e.g., DAPPV, Distemper, Adenovirus, Parvovirus, Parainfluenza). This substitution represents a landmark achievement in veterinary vaccinology, where a less pathogenic but antigenically related virus is used safely as a surrogate immunogen.

Mechanisms of Vaccine-Induced Immunity: Commercially available vaccines predominantly contain modified-live virus (MLV) CAV-2, often administered via the parenteral (injectable) or intranasal route. Both routes stimulate the production of neutralizing antibodies, primarily directed against the hexon and fiber proteins. Neutralizing antibodies are critical for preventing viral attachment and entry into host cells, particularly in the upper and lower respiratory tract. Intranasal vaccines have the additional advantage of inducing a robust local mucosal immune response, including secretory IgA, which provides the first line of defense at the portal of entry, thereby more rapidly reducing viral replication and shedding upon subsequent exposure [11]. While parenteral vaccines effectively prevent systemic disease, they may not fully prevent infection of the respiratory mucosa, which is why intranasal administration is often preferred for high-risk populations, such as those in kennels and shelters.

Efficacy and Epidemiological Impact in Shelter Environments: The profound impact of vaccination, even in the face of an ongoing outbreak, was demonstrated in a study at an animal shelter. The implementation of a vaccination-on-intake protocol using a multivalent DAPPv and intranasal Bb/CPIV vaccine led to a statistically significant decrease in the proportion of dogs coughing. When vaccination coverage exceeded 90%, the prevalence of coughing decreased by approximately 7% compared to periods when coverage was lower [26]. This finding is critical. It proves that vaccination is not merely a prophylactic tool but can interrupt active transmission cycles within high-density populations. The study further noted that the shelter was experiencing a CIRD outbreak, demonstrating that even when exposure is ubiquitous, increasing population-level immunity can decelerate or halt the progression of clinical signs [26]. This supports the concept of herd immunity, where a sufficient proportion of the population is immune, thereby protecting vulnerable individuals (e.g., young puppies, immunosuppressed dogs) by breaking the chain of infection.

Challenges in Vaccination: The Interference with Diagnostic PCR: A significant operational challenge with MLV CAV-2 vaccines, particularly for clinicians and diagnostic laboratories, is the detection of vaccine-derived viral nucleic acids in post-vaccination samples. A prospective study demonstrated that nucleic acids from all three components of a topical intranasal vaccine (CAV-2, B. bronchiseptica, and CPIV) were detectable by PCR from nasal and pharyngeal swabs for up to 28 days post-vaccination, with the highest proportion of positive samples occurring between days 3 and 10 [11]. This creates a critical diagnostic conundrum: a positive PCR result in a recently vaccinated dog cannot reliably distinguish between vaccine virus and a field strain causing natural disease. This can lead to false-positive diagnoses and unnecessary treatment or quarantine decisions. The authors rightly concluded that vaccine status is an indispensable variable when interpreting respiratory pathogen PCR results. The development of quantitative PCR assays or wild-type-specific sequencing is needed to differentiate vaccinal from virulent strains and improve the positive predictive value of these diagnostic tools [11].

Vaccine Strain Evolution and Genetic Divergence: The assumption of uniform vaccine efficacy is challenged by evidence of genetic drift among circulating CAV-2 strains. Genomic analyses of CAV-2 isolates from China have revealed that the fiber gene sequences of field strains share only 79.0–80.5% nucleotide and 77.3–80.5% amino acid identity with the commonly used vaccine strain CLL [12]. The fiber protein, which mediates viral attachment to host cell receptors, is a primary target for neutralizing antibodies. Substantial divergence in this region raises the specter of reduced vaccine cross-protection against emerging field strains. Furthermore, this same study identified a novel genotype based on the hexon gene sequence, which is the major capsid protein and another key antigenic target [12]. These findings underscore the necessity for continuous global surveillance of CAV-2 genetic diversity to ensure that vaccine strains remain antigenically relevant. The detection of vaccine-origin CAV-2 strains (closely related to Toronto A26/61) in wild raccoon dogs in Korea further complicates the epidemiological picture, suggesting that vaccine virus can spill over into wildlife populations [7]. While this does not implicate the vaccine in causing disease in wildlife, it raises important questions about the long-term ecological impacts of widespread vaccine use and the potential for recombination between vaccine and wild-type strains.

CAV-2 as a Vector Platform for Other Vaccines: Beyond its role as a direct immunogen, the replication-defective CAV-2 vector has been successfully engineered as a platform for delivering heterologous antigens. This technology has been applied to develop experimental vaccines against porcine reproductive and respiratory syndrome virus (PRRSV) by expressing GP5 and M proteins [20] and against foot-and-mouth disease virus (FMDV) by expressing the structural P1 precursor protein and the 3C protease [10]. In the FMDV guinea pig model, the CAV-2 vectored vaccine (Cav-P1/3C R°) elicited a strong humoral immune response and provided protection against challenge comparable to a high-potency conventional vaccine [10]. This demonstrates the versatility of the CAV-2 backbone for developing marker vaccines that can differentiate infected from vaccinated animals, a key tool for disease control and eradication campaigns. The potential for CAV-2 vectors to induce mucosal immunity, as suggested by studies with human adenovirus-based SARS-CoV-2 vaccines [43], also suggests a future path for intranasal, needle-free immunization against CIRD.

Biosecurity: A Critical Adjunct to Vaccination

Vaccination alone, while indispensable, is rarely sufficient to control CAV-2 within a population, particularly in high-density, high-stress environments such as animal shelters, boarding kennels, and breeding facilities. Biosecurity measures are essential to reduce pathogen introduction, transmission, and environmental persistence.

Transmission Mechanics and Environmental Persistence: CAV-2 is transmitted primarily via direct contact with infected respiratory secretions (aerosols, droplets, fomites). The virus is non-enveloped, a structural characteristic that confers significant environmental stability. It can persist on surfaces, in bedding, and in food/water bowls for extended periods, resisting many common disinfectants. Effective biosecurity must therefore target both direct and indirect transmission pathways.

Crucial Biosecurity Protocols for High-Risk Facilities:

1. Isolation and Quarantine: All incoming dogs, particularly those with unknown or incomplete vaccination histories, should be immediately segregated from the resident population for a minimum of 7–10 days, consistent with the incubation period of CIRD pathogens. This includes dedicated housing, airspace, and handling equipment. Asymptomatic carriers are a major source of pathogen introduction; a single dog may shed CAV-2 without displaying overt clinical signs, and studies have shown that co-infections are common [3, 21].

2. Cohorting and Zoning: Within a facility, dogs should be grouped based on health status, vaccination history, and known pathogen exposure. High-risk areas (e.g., intake wards, isolation units) must be physically separated from low-risk areas (e.g., adoption floors). Staff movement should follow a unidirectional pattern from clean (low-risk) to dirty (high-risk) zones to prevent fomite transfer.

3. Environmental Disinfection: Given the resilience of adenoviruses, the choice of disinfectant is critical. Quaternary ammonium compounds, accelerated hydrogen peroxide, and bleach (sodium hypochlorite) are effective against non-enveloped viruses. However, organic matter (feces, saliva) can inactivate disinfectants. Therefore, a rigorous two-step process, cleaning with a detergent to remove organic debris, followed by application of an appropriate disinfectant with adequate contact time, is mandatory.

4. Hand Hygiene and Personal Protective Equipment (PPE): Personnel should perform hand hygiene with soap and water or an alcohol-based hand rub after handling each animal or contaminated material. The use of dedicated footwear and outerwear (e.g., coveralls, boot covers) in high-risk zones is non-negotiable.

5. Ventilation and Air Hygiene: CAV-2 can be transmitted over short distances via aerosols. Optimizing ventilation rates to dilute and remove airborne pathogens is crucial. Negative pressure isolation rooms for infected animals are ideal. Ultraviolet germicidal irradiation (UVGI) in air handling ducts can also be effective.

6. Population Management: Limiting population density is one of the most effective but often overlooked biosecurity measures. Overcrowding increases stress, which immunosuppresses animals and elevates shedding rates. Reducing the number of animals in a given space or cohort can significantly lower transmission risk.

Surveillance and Diagnostic Stewardship: A biosecurity plan must be data-driven. The use of advanced, multiplex molecular diagnostics is key to identifying the pathogens circulating within a population. Comprehensive panels, such as those targeting 9 or 12 CIRDC pathogens, allow for rapid detection of CAV-2, CRCoV, CPIV, M. cynos, and other agents [21, 25, 29]. These panels are invaluable for confirming the etiology of an outbreak and for identifying co-infections, which are associated with more severe clinical outcomes [46]. Regular surveillance, even in clinically healthy populations, can reveal subclinical carriers [36]. The development of rapid, point-of-care tests, such as recombinase polymerase amplification (RPA) assays, which can detect CAV-2 within 15 minutes at 39°C, promises to revolutionize outbreak response in field settings [40]. Such tools enable immediate decision-making regarding isolation and treatment, without the delay of sending samples to an external laboratory.

The Role of Public Health and International Standards: While CAV-2 is not a zoonotic pathogen, the principles of biosecurity for CIRD align with the broader One Health framework. The World Organisation for Animal Health (WOAH) guidelines for the management of infectious diseases in animal populations emphasize the importance of surveillance, quarantine, and movement control. The Centers for Disease Control and Prevention (CDC) and the FAO do not specifically target CAV-2, but their frameworks for outbreak investigation and control of respiratory viruses in human populations provide a template for best practices in veterinary settings. The high prevalence of subclinical infections in shelter dogs [36] highlights that reliance on clinical diagnosis alone is insufficient; systematic surveillance programs, modeled on those used for influenza and SARS-CoV-2 in humans, are needed to track CAV-2 circulation and inform vaccination strategies.

Integrated Control: The Synergy of Vaccination and Biosecurity

The most effective control programs for CAV-2 are those that synergistically combine vaccination and biosecurity. Vaccination reduces the number of susceptible animals and lowers the intensity of shedding if infection occurs. Biosecurity reduces the opportunity for the pathogen to reach those susceptible animals. In an outbreak scenario, rapid implementation of both measures is imperative. Vaccination can be administered on intake to immunize naïve animals even before their antibody titers are protective, while strict quarantine prevents the newly arriving animal from exposing the existing population during the window of vulnerability [26]. This integrated approach was the key to reducing clinical signs in the shelter study [26] and is the foundation for controlling CIRD in any setting where dogs congregate.

In conclusion, the control of CAV-2 is a dynamic interplay between immunological protection and environmental management. While current vaccines are highly effective, ongoing genetic surveillance is needed to ensure they remain relevant. The development of novel, mucosal-based vaccine vectors may further enhance protection. Simultaneously, rigorous biosecurity protocols, supported by modern molecular diagnostics, are essential to limit pathogen spread and protect the most vulnerable canine populations.

Future Perspectives and Research Gaps in CAV-2 Respiratory Disease

The evolving landscape of canine infectious respiratory disease complex (CIRDC) demands a paradigm shift in how we approach canine adenovirus type 2 (CAV-2) research. Despite decades of vaccination and a perceived decline in clinical significance, mounting evidence suggests that our current understanding of CAV-2 pathogenesis, epidemiology, and host-pathogen interactions remains critically incomplete. The emergence of novel molecular tools, the recognition of previously unappreciated genetic diversity, and the shifting ecological dynamics of respiratory pathogens in the post-COVID-19 era collectively expose substantial research gaps that must be addressed to safeguard canine health.

The Diagnostic Conundrum: Differentiating Vaccine from Wild-Type Infection

One of the most pressing and overlooked challenges in CAV-2 research is the inability of standard molecular diagnostics to distinguish between vaccine strains and field isolates. Ruch-Gallie et al. [11] demonstrated that modified live intranasal vaccines containing CAV-2, Bordetella bronchiseptica, and parainfluenza virus can produce positive PCR results from nasal and pharyngeal swabs for up to 28 days post-vaccination, with peak detection between days 3 and 10. This finding has profound implications for clinical interpretation and epidemiological surveillance. The positive predictive value of current PCR assays for diagnosing active CAV-2 disease is substantially degraded in vaccinated populations, particularly in shelter environments where animals may have unknown or recent vaccine histories.

The research community has not yet established reliable molecular markers or quantitative thresholds that reliably differentiate vaccine from wild-type virus. While sequencing of specific genomic regions, such as the E3 gene, which exhibits hypervariability in field isolates, offers theoretical promise [5, 6], this approach is not practical for routine diagnostic workflows. The development of wild-type-specific PCR assays, perhaps targeting genomic deletions or insertions unique to circulating strains, is an urgent priority. Furthermore, the finding that Indian CAV-2 isolates possess a unique guanine nucleotide insertion at position 1077 in the E3 gene, resulting in an extended C-terminal end of the E3 protein [6], highlights the potential for geographically distinct molecular signatures that could be exploited for diagnostic discrimination. Without such tools, our current epidemiological data on CAV-2 prevalence may be significantly confounded by vaccine-derived signals.

Unraveling the Genetic and Antigenic Drift of Circulating Strains

The perception that CAV-2 is a genetically stable virus, largely controlled by existing vaccines, is increasingly untenable. Ji et al. [12] provided compelling evidence of substantial genetic diversification among CAV-2 strains circulating in central China between 2017 and 2019. Their analysis of the fiber, hexon, and penton genes revealed that the fiber gene is the most variable, sharing only 79.0–80.5% nucleotide identity with the vaccine strain CLL. Crucially, the amino acid mutations in the fiber protein were localized to the head region, which is responsible for receptor binding and tropism determination. This finding raises the disturbing possibility that antigenic drift in the fiber protein could alter cellular tropism, immune escape profiles, or both.

Moreover, the identification of a novel CAV-2 genotype based on hexon gene analysis of Chinese and Indian strains [6, 12] suggests that existing phylogenetic classifications may be inadequate. Timurkan et al. [5] further refined this view, demonstrating that CAV-2 isolates can be divided into at least two subgroups: an America-Europe clade and a China-Turkey clade, with nine amino acid differences distinguishing them in the E3 gene. These genetic distinctions may translate into functional differences in virulence, transmissibility, or vaccine cross-protection. Current vaccines are derived from strains such as Toronto A26/61 [7, 16], which cluster within the America-Europe clade. Whether these vaccines provide equivalent protection against the China-Turkey clade isolates remains experimentally untested. The research community must prioritize comprehensive, multi-regional whole-genome sequencing efforts to establish a robust phylogenetic framework and to monitor the emergence of vaccine-escape variants in real time.

The Polypathogen Synergy: Understanding CAV-2 in the Context of Coinfections

A recurrent and sobering theme across multiple epidemiological studies is that CAV-2 is rarely detected as a sole pathogen in clinical disease. Yondo et al. [2] reported that among 459 cases of CIRDC, CAV-2 was identified in only 4% of cases, while co-infections with two or more pathogens occurred in 24% of cases. Similarly, Maboni et al. [4] emphasized that co-infections significantly exacerbate clinical severity, with host factors such as age being the strongest predictors of outcome. The mechanistic basis for this synergy remains largely unexplored. Does CAV-2 infection disrupt mucociliary clearance, facilitating bacterial adherence and invasion? Does CAV-2-induced immunosuppression, perhaps mediated by the E3 gene product, permit the unchecked replication of other viruses? Does prior infection with canine respiratory coronavirus (CRCoV) or Mycoplasma species modulate the host response to CAV-2 in a manner that alters disease trajectory? These fundamental questions remain unanswered.

The development of high-throughput multiplex diagnostic panels [1, 21, 25, 29] now makes it feasible to characterize the entire polymicrobial landscape of the canine respiratory tract in health and disease. However, these tools have not been systematically applied to prospective, longitudinal studies that track the temporal sequence of pathogen acquisition and clearance. Such studies are essential to establish causality rather than mere association. Furthermore, the role of newly emerging pathogens such as canine pneumovirus (CPnV) [34, 41, 50] and canine circovirus (CanineCV) [47] in modulating CAV-2 pathogenesis is entirely unknown. The detection of CanineCV DNA in pulmonary tissues and associated lymphoid cells [47] raises the possibility that these novel agents may act as co-factors in CAV-2-associated disease, a hypothesis that warrants rigorous investigation.

Wildlife Reservoirs and Cross-Species Transmission Dynamics

The detection of CAV-2 in wild carnivore populations introduces a critical One Health dimension to CAV-2 research that has been largely ignored. Kim et al. [7] isolated CAV-2 from wild raccoon dogs in Korea, and phylogenetic analysis revealed near-identity with the vaccine strain Toronto A26/61, suggesting transmission from vaccinated companion animals to wildlife. This finding has profound implications for vaccine safety and environmental contamination. Similarly, serological surveys have documented CAV-2 antibodies in raccoon dogs, cattle, sows, horses, and even cats [32], indicating that the host range of CAV-2 may be considerably broader than previously appreciated. The potential for CAV-2 to establish sylvatic cycles, as has been well-documented for CAV-1 in red foxes [9] and wolves [31, 48], represents a significant knowledge gap. If CAV-2 can persist in wildlife reservoirs, it could serve as a continuous source of reintroduction into domestic dog populations, undermining eradication efforts and potentially driving the selection of novel variants through host adaptation. Long-term surveillance of CAV-2 in wild canids, mustelids, and other potential reservoir species is urgently needed, particularly in regions where domestic dog vaccination coverage is high but wildlife-livestock interfaces are porous.

Immunological Correlates of Protection and the Need for Next-Generation Vaccines

The current vaccine paradigm for CAV-2 relies on modified live virus strains that were developed decades ago [17]. While these vaccines have undoubtedly reduced the incidence of severe respiratory disease, they are not without limitations. Intranasal vaccines can elicit false-positive PCR results for weeks post-vaccination [11], and the durability of mucosal immunity induced by parenteral vaccines is not well characterized. Furthermore, the correlate of protection for CAV-2 has never been rigorously defined. Is protection mediated primarily by neutralizing antibodies, by cellular immune responses, or by a combination of both? Do current vaccine strains generate cross-protective immunity against the genetically diverse field isolates now circulating in Asia and Europe? These are not merely academic questions; they have direct bearing on vaccine efficacy and the potential for vaccine-driven selection of escape mutants.

The use of CAV-2 as a viral vector for vaccine delivery and gene therapy [10, 13, 19, 20] has paradoxically generated more immunological data in the context of heterologous antigen expression than for CAV-2 itself. Studies demonstrating that replication-defective CAV-2 vectors can elicit robust humoral and cellular immune responses against foot-and-mouth disease virus [10] and porcine reproductive and respiratory syndrome virus [20] underscore the immunogenicity of the CAV-2 backbone. However, the immune responses elicited by the vector backbone against native CAV-2 antigens in vaccinated animals have not been systematically profiled using modern immunological tools. The application of systems serology, B-cell receptor sequencing, and T-cell epitope mapping to CAV-2 vaccine responses could identify the specific antigenic targets and immune mechanisms that confer durable protection.

Implications of the Post-COVID-19 Epidemiological Shift

The SARS-CoV-2 pandemic has dramatically altered the circulation patterns of respiratory viruses in both human and animal populations. In humans, adenovirus activity in South Korea surged to 42.2% detection rates in the summer of 2023, a dramatic increase from pre-pandemic levels [35], while in China, the relaxation of non-pharmaceutical interventions led to a concurrent rise in adenovirus and influenza A infections [38]. The disruption of normal viral seasonality and the potential for immune debt may have analogous consequences for canine respiratory viruses, including CAV-2. Dogs, which can be infected with SARS-CoV-2 [21, 49], may have experienced altered exposure patterns to other respiratory pathogens during lockdowns and reduced social contact. The impact of these ecological disruptions on CAV-2 transmission dynamics, outbreak frequency, and clinical severity is completely unknown. Baseline surveillance data from the pre-pandemic period is limited, making it difficult to assess whether CAV-2 activity has increased, decreased, or changed in character. Establishing sentinel surveillance programs that monitor CAV-2 in parallel with other CIRDC pathogens across diverse geographic regions and management settings (shelters, kennels, private households) is essential to detect emerging trends and to inform timely interventions.

The Uncharted Territory of CAV-2 Pathogenesis and Host Response

Finally, fundamental questions about CAV-2 pathogenesis remain unanswered. The mechanisms by which CAV-2 damages the respiratory epithelium, evades host immune responses, and predisposes to secondary bacterial infections are not well understood at the molecular level. The parallels with human adenovirus (HAdV) pathogenesis are instructive but underutilized. In humans, severe HAdV infections are associated with a profound cytokine storm involving IL-6, IL-10, IFN-γ, and M-CSF, and these biomarkers can predict disease progression and outcomes [24]. Whether similar immune dysregulation occurs in CAV-2-infected dogs is unknown. The availability of CAV-2 genomic sequences, the development of reverse genetics systems, and the establishment of canine respiratory epithelial cell culture models should now permit detailed mechanistic studies of viral entry, replication, and host antiviral responses. The identification of cellular receptors for CAV-2, which remain poorly characterized, would represent a major advance, potentially revealing targets for antiviral intervention.

In summary, the future of CAV-2 research must move beyond descriptive prevalence studies toward hypothesis-driven mechanistic investigation, informed by modern genomic, immunological, and ecological frameworks. The tools are now available; the will to apply them to this historically neglected pathogen must follow. The canine populations in our care, whether companion animals, shelter residents, or working dogs, deserve nothing less.

References

[1] Shi K, Shi Y, Shi Y, Long F, Yin Y, Pan Y, et al.. Establishment of a Quadruplex RT-qPCR for the Detection of Canine Coronavirus, Canine Respiratory Coronavirus, Canine Adenovirus Type 2, and Canine Norovirus. Pathogens. 2024. DOI: https://doi.org/10.3390/pathogens13121054

[2] Yondo A, Kalantari A, Fernandez-Marrero I, McKinney A, Naikare HK, Velayudhan B. Predominance of Canine Parainfluenza Virus and Mycoplasma in Canine Infectious Respiratory Disease Complex in Dogs. Pathogens. 2023. DOI: https://doi.org/10.3390/pathogens12111356

[3] Day MJ, Carey S, Clercx C, Kohn B, Marsilio F, Thiry E, et al.. Aetiology of Canine Infectious Respiratory Disease Complex and Prevalence of its Pathogens in Europe. Journal of Comparative Pathology. 2020. DOI: https://doi.org/10.1016/j.jcpa.2020.02.005

[4] Maboni G, Seguel M, Lorton A, Berghaus R, Sanchez S. Canine infectious respiratory disease: New insights into the etiology and epidemiology of associated pathogens. PLoS ONE. 2019. DOI: https://doi.org/10.1371/journal.pone.0215817

[5] Timurkan M, Aydın H, Alkan F. Detection and molecular characterization of canine adenovirus type 2 (CAV-2) in dogs with respiratory tract symptoms in shelters in Turkey. Veterinarski arhiv (Tisak). 2018. DOI: https://doi.org/10.24099/VET.ARHIV.0052

[6] Chander V, Sharma G, Bhatt M, Nandi S, Mahajan S, Singh M, et al.. Isolation and genetic characterization of canine adenovirus type 2 from a domestic dog showing neurological symptoms. Brazilian Journal of Microbiology. 2021. DOI: https://doi.org/10.1007/s42770-021-00540-0

[7] Kim Y, Lee S, Kim Y, Na E, Park J, Oem J. Genetic Characteristics of Canine Adenovirus Type 2 Detected in Wild Raccoon Dogs (Nyctereutes procyonoides) in Korea (2017–2020). Veterinary Sciences. 2022. DOI: https://doi.org/10.3390/vetsci9110591

[8] Hograindleur M, Effantin G, Fenel D, Mas C, Lieber A, Schoehn G, et al.. Binding Mechanism Elucidation of the Acute Respiratory Disease Causing Agent Adenovirus of Serotype 7 to Desmoglein-2. Viruses. 2020. DOI: https://doi.org/10.3390/v12101075

[9] Walker D, Fee S, Hartley G, Learmount J, O'Hagan M, Meredith A, et al.. Serological and molecular epidemiology of canine adenovirus type 1 in red foxes (Vulpes vulpes) in the United Kingdom. Scientific Reports. 2016. DOI: https://doi.org/10.1038/srep36051

[10] Vleeschauwer ADD, Zhou X, Lefebvre D, Garnier A, Watier F, Pignon C, et al.. A canine adenovirus type 2 vaccine vector confers protection against foot-and-mouth disease in guinea pigs.. Vaccine. 2018. DOI: https://doi.org/10.1016/j.vaccine.2018.02.074

[11] Ruch-Gallie R, Moroff S, Lappin MR. Adenovirus 2, Bordetella bronchiseptica, and Parainfluenza Molecular Diagnostic Assay Results in Puppies After vaccination with Modified Live Vaccines. Journal of Veterinary Internal Medicine. 2015. DOI: https://doi.org/10.1111/jvim.13821

[12] Ji J, Li W, Hu W, Xu X, Kan Y, Yao L, et al.. Novel Genotype Definition and the First Epidemiological Investigation of Canine Adenovirus Type 2 in Dogs in Central China. Frontiers in Veterinary Science. 2020. DOI: https://doi.org/10.3389/fvets.2020.00534

[13] Martel A, Elseedy H, Lavigne M, Scapula J, Ghestem A, Kremer E, et al.. Targeted Transgene Expression in Cholinergic Interneurons in the Monkey Striatum Using Canine Adenovirus Serotype 2 Vectors. Frontiers in Molecular Neuroscience. 2020. DOI: https://doi.org/10.3389/fnmol.2020.00076

[14] Headley SA, Oliveira TE, Pereira AHT, Moreira JR, Michelazzo MZ, Pires BG, et al.. Canine morbillivirus (canine distemper virus) with concomitant canine adenovirus, canine parvovirus-2, and Neospora caninum in puppies: a retrospective immunohistochemical study. Scientific Reports. 2018. DOI: https://doi.org/10.1038/s41598-018-31540-0

[15] Opperman S, Brownlie J. Respiratory disease in the dog in the shelter environment. BSAVA Manual of Canine and Feline Shelter Medicine. 2018. DOI: https://doi.org/10.22233/9781910443330.14

[16] Yang D, Kim HH, Yoon S, Lee H, Cho I. Isolation and identification of canine adenovirus type 2 from a naturally infected dog in Korea. Korean Journal of Veterinary Research. 2018. DOI: https://doi.org/10.14405/KJVR.2018.58.4.177

[17] Mj A, Si B, Menegus M, Da A, Le C. Pathogenicity of low-virulence strains of two canine adenovirus types.. American Journal of Veterinary Research. 1973. DOI: https://doi.org/10.2460/ajvr.1973.34.04.543

[18] Hamelin C, Jouvenne P, Assaf R. Genotypic characterization of type-2 variants of canine adenovirus.. American Journal of Veterinary Research. 1986. DOI: https://doi.org/10.2460/ajvr.1986.47.03.625

[19] Carinhas N, Pais DAM, Koshkin A, Fernandes P, Coroadinha AS, Carrondo M, et al.. Metabolic flux profiling of MDCK cells during growth and canine adenovirus vector production. Scientific Reports. 2016. DOI: https://doi.org/10.1038/srep23529

[20] Cai J, Ma Y, Li J, Yan C, Hu R, Zhang J. Construction and characterization of a recombinant canine adenovirus expressing GP5 and M proteins of porcine reproductive and respiratory syndrome virus.. Journal of Veterinary Medical Science. 2010. DOI: https://doi.org/10.1292/JVMS.10-0061

[21] Thieulent CJ, Carossino M, Peak L, Strother K, Wolfson W, Balasuriya UBR. Development and Validation of a Panel of One-Step Four-Plex qPCR/RT-qPCR Assays for Simultaneous Detection of SARS-CoV-2 and Other Pathogens Associated with Canine Infectious Respiratory Disease Complex. Viruses. 2023. DOI: https://doi.org/10.3390/v15091881

[22] Balboni A, Terrusi A, Urbani L, Troìa R, Stefanelli SAM, Giunti M, et al.. Canine circovirus and Canine adenovirus type 1 and 2 in dogs with parvoviral enteritis. Veterinary research communications. 2021. DOI: https://doi.org/10.1007/s11259-021-09850-y

[23] Tryland M, Balboni A, Killengreen S, Mørk T, Nielsen O, Yoccoz N, et al.. A screening for canine distemper virus, canine adenovirus and carnivore protoparvoviruses in Arctic foxes (Vulpes lagopus) and red foxes (Vulpes vulpes) from Arctic and sub-Arctic regions of Norway. Polar Research. 2018. DOI: https://doi.org/10.1080/17518369.2018.1498678

[24] Li J, Wei J, Xu Z, Jiang C, Li M, Chen J, et al.. Cytokine/Chemokine Expression Is Closely Associated Disease Severity of Human Adenovirus Infections in Immunocompetent Adults and Predicts Disease Progression. Frontiers in Immunology. 2021. DOI: https://doi.org/10.3389/fimmu.2021.691879

[25] Dong J, Tsui W, Leng X, Fu J, Lohman M, Anderson J, et al.. Validation of a real-time PCR panel for detection and quantification of nine pathogens commonly associated with canine infectious respiratory disease. MethodsX. 2023. DOI: https://doi.org/10.1016/j.mex.2023.102476

[26] Andrukonis A, Brown KM, Hall NJ, Protopopova A. Intake Vaccinations Reduced Signs of Canine Respiratory Disease During an Outbreak at an Animal Shelter. Frontiers in Veterinary Science. 2021. DOI: https://doi.org/10.3389/fvets.2021.627580

[27] Piewbang C, Rungsipipat A, Poovorawan Y, Techangamsuwan S. Cross-sectional investigation and risk factor analysis of community-acquired and hospital-associated canine viral infectious respiratory disease complex. Heliyon. 2019. DOI: https://doi.org/10.1016/j.heliyon.2019.e02726

[28] Hiebl A, Auer A, Bagrinovschi G, Stejskal M, Hirt R, Rümenapf HT, et al.. Detection of selected viral pathogens in dogs with canine infectious respiratory disease in Austria. Journal of Small Animal Practice. 2019. DOI: https://doi.org/10.1111/jsap.13051

[29] Dong J, Tsui W, Leng X, Fu J, Lohman M, Anderson J, et al.. Development of a three-panel multiplex real-time PCR assay for simultaneous detection of nine canine respiratory pathogens.. Journal of Microbiological Methods. 2022. DOI: https://doi.org/10.1016/j.mimet.2022.106528

[30] Matsuu A, Yabuki M, Aoki E, Iwahana M. Molecular detection of canine respiratory pathogens between 2017 and 2018 in Japan. Journal of Veterinary Medical Science. 2020. DOI: https://doi.org/10.1292/jvms.20-0017

[31] Canuti M, Fry K, Cluff HD, Mira F, Fenton H, Lang A. Co-circulation of five species of dog parvoviruses and canine adenovirus type 1 among gray wolves (Canis lupus) in northern Canada.. Transboundary and Emerging Diseases. 2022. DOI: https://doi.org/10.1111/tbed.14474

[32] Yang D, Kim H, Yoon S, Ji M, Cho I. Incidence and Sero-survey of Canine Adenovirus Type 2 in Various Animal Species. Journal of Bacteriology and Virology. 2018. DOI: https://doi.org/10.4167/JBV.2018.48.3.102

[33] Chethan G, Singh M, Chander V, Akhilesh, Singh D, Rajesh J, et al.. Occurrence of Canine parvovirus-2 and Canine adenovirus-1 Infections in Dogs: A Hospital Based Study. Indian Journal of Animal Research. 2020. DOI: https://doi.org/10.18805/IJAR.B-3936

[34] More G, Cave N, Biggs P, Acke E, Dunowska M. A molecular survey of canine respiratory viruses in New Zealand. New Zealand Veterinary Journal. 2021. DOI: https://doi.org/10.1080/00480169.2021.1915211

[35] Lee N, Woo S, Rhee J, Lee J, Lee S, Kim E. Increased Trend of Adenovirus Activity After the COVID-19 Pandemic in South Korea: Analysis of National Surveillance Data. Annals of Laboratory Medicine. 2024. DOI: https://doi.org/10.3343/alm.2023.0484

[36] Lavan R, Knesl O. Prevalence of canine infectious respiratory pathogens in asymptomatic dogs presented at US animal shelters. Journal of Small Animal Practice. 2015. DOI: https://doi.org/10.1111/jsap.12389

[37] Miyasaki CYP, Gonçalves RL, Krys P, Pereira L, Petterle R, Giamberardino H, et al.. Cross-sectional Study About Respiratory Viruses and the SARS-CoV-2 Pandemic in Southern Brazil: Results of a Prospective Epidemiologic Active Surveillance Study.. The Pediatric Infectious Disease Journal. 2025. DOI: https://doi.org/10.1097/INF.0000000000004812

[38] Zhao P, Zhang Y, Wang J, Li Y, Wang Y, Gao Y, et al.. Epidemiology of respiratory pathogens in patients with acute respiratory infections during the COVID‐19 pandemic and after easing of COVID‐19 restrictions. Microbiology spectrum. 2024. DOI: https://doi.org/10.1128/spectrum.01161-24

[39] Piewbang C, Rungsipipat A, Poovorawan Y, Techangamsuwan S. Viral molecular and pathological investigations of Canid herpesvirus 1 infection associated respiratory disease and acute death in dogs. Acta Veterinaria. 2017. DOI: https://doi.org/10.1515/acve-2017-0002

[40] Xiao L, Zhang M, Tian Z, Ge Y, Zhang T, Yi L, et al.. Development of a Recombinase Polymerase Amplification Fluorescence Assay for the Detection of Canine Adenovirus 2. Frontiers in Veterinary Science. 2021. DOI: https://doi.org/10.3389/fvets.2021.596877

[41] Song X, Li Y, Huang J, Cao H, Zhou Q, Sha X, et al.. An emerging orthopneumovirus detected from dogs with canine infectious respiratory disease in China.. Transboundary and Emerging Diseases. 2021. DOI: https://doi.org/10.1111/tbed.14291

[42] Hao X, Liu R, He Y, Xiao X, Xiao W, Zheng Q, et al.. Multiplex PCR methods for detection of several viruses associated with canine respiratory and enteric diseases. PLoS ONE. 2019. DOI: https://doi.org/10.1371/journal.pone.0213295

[43] Langel S, Johnson S, Martinez CI, Tedjakusuma SN, Peinovich N, Dora E, et al.. Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model. Science Translational Medicine. 2022. DOI: https://doi.org/10.1126/scitranslmed.abn6868

[44] Piewbang C, Rungsipipat A, Poovorawan Y, Techangamsuwan S. Development and application of multiplex PCR assays for detection of virus-induced respiratory disease complex in dogs. Journal of Veterinary Medical Science. 2016. DOI: https://doi.org/10.1292/jvms.16-0342

[45] Sowman H, Cave N, Dunowska M. A survey of canine respiratory pathogens in New Zealand dogs. New Zealand Veterinary Journal. 2018. DOI: https://doi.org/10.1080/00480169.2018.1490214

[46] Probst V, Spieker A, Stopczynski T, Stewart LS, Haddadin Z, Selvarangan R, et al.. Clinical Presentation and Severity of Adenovirus Detection Alone vs Adenovirus Co-detection With Other Respiratory Viruses in US Children With Acute Respiratory Illness from 2016 to 2018.. Journal of the Pediatric Infectious Diseases Society. 2022. DOI: https://doi.org/10.1093/jpids/piac066

[47] Dankaona W, Mongkholdej E, Satthathum C, Piewbang C, Techangamsuwan S. Epidemiology, genetic diversity, and association of canine circovirus infection in dogs with respiratory disease. Scientific Reports. 2022. DOI: https://doi.org/10.1038/s41598-022-19815-z

[48] Oleaga Á, Balseiro A, Espí A, Royo L. Wolf (Canis lupus) as canine adenovirus type 1 (CAdV-1) sentinel for the endangered Cantabrian brown bear (Ursus arctos arctos).. Transboundary and Emerging Diseases. 2021. DOI: https://doi.org/10.1111/tbed.14010

[49] Michael H, Waterhouse T, Estrada M, Seguin M. Frequency of respiratory pathogens and SARS‐CoV‐2 in canine and feline samples submitted for respiratory testing in early 2020. Journal of Small Animal Practice. 2021. DOI: https://doi.org/10.1111/jsap.13300

[50] Priestnall S, Mitchell J, Walker C, Erles K, Brownlie J. New and Emerging Pathogens in Canine Infectious Respiratory Disease. Veterinary Pathology-Supplement. 2014. DOI: https://doi.org/10.1177/0300985813511130